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Abstract 
Background: Retinal ischemia is a retinal disorder related to retinal vascular occlusion, glaucoma, diabetic retin‑
opathy and age‑related macular degeneration. The study aimed to evaluate the protective effects and underlying 
mechanisms of Chi‑Ju‑Di‑Huang‑Wan (CJDHW) against retinal ischemia in rats.
Methods: High intraocular pressure (HIOP)‑induced retinal ischemia was established in Wistar rats by raising their 
intraocular pressure to 120 mmHg for 60 min with in an eye whose anterior chamber was cannulated with a 30‑guage 
needle adapted to a normal saline bottle through an intravenous line. This ischemic insult was followed by 1 or 7 days of 
reperfusion. The effects of CJDHW were studied by (i) electroretinogram (ERG); (ii) real‑time polymerase chain reaction to 
determine the retinal mRNA levels of Thy‑1 and matrix metalloproteinase‑9 (MMP‑9); (iii) Western blot analysis to deter‑
mine the retinal protein levels of B cell lymphoma 2 (Bcl‑2), heme oxygenase‑1 (HO‑1), phosphorylated‑p38 mitogen‑
activated protein kinase (P‑p38 MAPK) and MMP‑9; (iv) hematoxylin and eosin (HE) staining; (v) fluorogold retrograde 
labeling; and (vi) terminal deoxynucleotidyl‑transferase (TdT)‑mediated dUTP nick end‑labeling (TUNEL) apoptosis assay. 
Moreover, after fixation with 4 % paraformaldehyde and 30 % sucrose, the isolated retinas were sectioned and immuno‑
labeled with goat anti‑choline acetyltransferase (ChAT) polyclonal antibody, mouse anti‑vimentin monoclonal antibody 
and rabbit anti‑glial fibrillary acidic protein (GFAP) polyclonal antibody. The retinal sections were then incubated with 
rhodamine‑conjugated rabbit anti‑goat antibody, fluorescein isothiocyanate (FITC)‑conjugated goat anti‑mouse IgG or 
FITC‑conjugated goat anti‑rabbit IgG. A daily oral intake of 3 mL of water (vehicle; Group 2) or CJDHW (2.8 or 4.2 g/kg/
day; CJDHW2.8 or CJDHW4.2; Group 3 or 4) was given for 7 consecutive days either before (preischemic drug administra‑
tion) or after HIOP‑induced retinal ischemic injury (postischemic drug administration). In Group 5, an intravitreal injection 
of 4 μL of 0.5 mM SB203580 (p38 MAPK inhibitor) was performed on the ischemic eye 15 min before retinal ischemia. The 
control rats received a sham procedure (Group 1) where the saline reservoir was not raised.
Results: The ischemia‑induced changes (Group 2) were significantly modulated by pretreating the rats with 4.2 g/kg/
day of CJDHW (Group 4; ERG: P < 0.001 on I/R day 7; HE stain: P < 0.001 on I/R day 7; TUNEL: P = 0.05 on I/R day 7; ret‑
rograde labeling: P = 0.007 on I/R day 7; Thy‑1 mRNA: P = 0.02; MMP‑9 mRNA: P < 0.001; Bcl‑2 protein: P = 0.02; HO‑1 
protein: P = 0.03; P‑p38 MAPK protein: P < 0.001; MMP‑9 protein: P = 0.02). These modulations included the following 
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Background
Retinal vascular occlusion, glaucoma, diabetic retinopa-
thy and age-related macular degeneration (AMD) are 
related to retinal ischemia [1–3]. The incidences of these 
diseases are 0.0018  % for central retinal artery occlu-
sion (CRAO) [4], 4  % for primary open angle glaucoma 
(in urban areas) [5], 2.9 % for sight-threatening diabetic 
retinopathy (type 2 diabetes) [6] and 0.36  % for AMD 
(age ≥40) [7]. Amacrines and their neuronal processes 
were susceptible to ischemia plus reperfusion (I/R) [1–
3, 8, 9]. I/R led to an increase in the immunolabeling of 
vimentin/glial fibrillary acidic protein (GFAP) in Mül-
ler cells [1, 8, 9]. Ischemia-induced retinal ganglion cell 
(RGC) death was correlated positively to a significant 
increase in MMP-9 activity [10]. Heme oxygenase-1 
(HO-1) is involved in the cellular response to oxidative 
stress and hypoxia, and elevated levels of HO-1 can pro-
tect against retinal ischemia and/or AMD via its antioxi-
dative activity [11, 12]. Mitogen-activated protein kinases 
(MAPKs) are involved in signal transduction pathways, 
and several members of the MAPK subfamily (e.g., JNK, 
p38 and ERK1/2) were implicated in neuronal injury and 
several diseases [13, 14]. The MAPK protein, p38, which 
is stimulated by various stresses, including ischemia and 
oxidative stress, is involved in apoptosis [13, 14].
Chi-Ju-Di-Huang-Wan (CJDHW) consists of several 
components, including Fructus lycii (Gou qi zi), Chry-
santhemi flos (Ju hua) and Liu Wei Di Huang Wan, 
Rehmanniae Radix Preparata (Shu di huang), Corni fruc-
tus (Shan zhu yu), Rhizoma Diocoreae (Shan yao), Poria 
(Fu ling), Cortex Moutan radicis (Mu dan pi) and Alis-
matis Rhizoma (Ze xie) [15]. Several active compounds 
have been identified in this mixture, including the antiox-
idants zeaxanthin and lutein from F. lycii and C. flos [16], 
and trehalose from R. radix preparata [17]. CJDHW has 
been reported to stabilize tear film, as well as decreasing 
abnormalities of the corneal epithelium to treat dry eyes 
[15]. However, the molecular mechanisms responsible for 
the effects of CJDHW remain unknown.
The study aimed to evaluate the protective effects 
and underlying mechanisms of Chi-Ju-Di-Huang-Wan 
(CJDHW) against retinal ischemia in rats. The effects and 
mechanisms of CJDHW were assessed by electrophysiology, 
retinal thickness, choline acetyltransferase (ChAT) immu-
nochemistry, vimentin/GFAP immunochemistry (indexing 
Müller cells), fluorogold retrograde RGC labeling, TUNEL 
staining (for apoptotic cells), Bcl-2/HO-1/phosphorylated-
p38 (P-p38)/MMP-9 protein level analysis and MMP-9 
activity (as measured by zymography), as well as by measur-
ing the mRNA expression levels of Thy-1 and MMP-9.
Methods
Animals
The Institutional Animal Care and Use Committee at 
Cheng Hsin General Hospital (CHGH; Taipei, Taiwan; 
Animal Experiment Approval No: CHIACUC 102-
08 approved all the animal experiments, which com-
plied with the Association for Research in Vision and 
Ophthalmology Statement for the Use of Animals in 
Ophthalmology and Vision Research. Six-week old sex-
matched Wistar rats (250–300 g; n = 136; BioLasco, Tai-
pei, Taiwan) were raised in a large plastic cage (Shineteh 
Instruments Co., Ltd., Taipei, Taiwan) of maximal six 
companions with the 40–60 % humidity and at 19–23 °C. 
They were maintained on a 12-h light/dark period with 
12–15 air exchanges/h. They were fed with food and 
water at liberty. The animal studies were performed fol-
lowing the ARRIVE guideline (Additional file 1).
Anesthesia was carried out by intraperitoneal adminis-
tration of ketamine (Pfizer, Taipei, Taiwan) (100  mg/kg) 
and xylazine (Sigma-Aldrich, St. Louis, USA) (5  mg/kg). 
Sodium pentobarbitone (SCI Pharmtech, Inc., Taiwan) 
(>140 mg/kg) was intraperitoneally administered to sacri-
fice the animals (Scientific Procedures Acts 1986) [18].
features (Group 2 vs. 4), increased ERG b‑wave amplitudes (0.38 ± 0.04 vs. 0.81 ± 0.03), increased inner retinal thick‑
ness (45.08 ± 2.85 vs. 67.98 ± 5.48 μm), increased ChAT immunolabeling, decreased vimentin/GFAP immunoreactiv‑
ity, less numerous apoptotic cells in the ganglion cell layer (1.40 ± 0.55 vs. 0.60 ± 0.55), and more numerous retinal 
ganglion cells (887.73 ± 158.18 vs. 1389.02 ± 53.20). Moreover, increased Thy‑1 (0.31 ± 0.15 vs. 0.78 ± 0.32) and 
decreased MMP‑9 mRNA levels were found (4.44 ± 0.84 vs. 1.13 ± 0.34), respectively. Furthermore, the Bcl‑2 protein 
level (0.78 ± 0.08 vs. 1.80 ± 0.34) was increased while the HO‑1 (0.99 ± 0.20 vs. 4.15 ± 2.08), P‑p38 MAPK (1.12 ± 0.18 
vs. 0.57 ± 0.18) and MMP‑9 levels were decreased (0.70 ± 0.23 vs. 0.39 ± 0.10). The ischemia‑associated increases in 
P‑p38 and MMP‑9 protein levels were also attenuated by 0.5 mM SB203580 (P‑p38 MAPK: 1.12 ± 0.18 vs. 0.18 ± 0.07, 
P < 0.001; MMP‑9: 0.70 ± 0.23 vs. 0.21 ± 0.07, P = 0.002). This was also the case to the MMP_enzyme activity (Group 2 
vs. 4: 5.03 ± 1.57 vs. 1.59 ± 0.47, P = 0.002; Group 2 vs. 5: 5.03 ± 1.57 vs. 1.35 ± 0.41, P = 0.001).
Conclusion: Treatment of the rats suffering from retinal ischemia with CJDHW inhibited apoptosis, increased antioxi‑
dative activity, downregulated MMP‑9 and inhibited p38 MAPK.
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Induction of retinal ischemia
After anesthesia, the rats were kept in a stereotaxic 
frame. A 120  mmHg high intraocular pressure (HIOP) 
was induced and maintained for 60  min by cannulat-
ing an eye’s anterior chamber with adapting a 30-gauge 
needle to a normal saline bottle, which was raised [19]. 
The induction of an ischemic insult was confirmed by the 
detection of a pale eye fundus [1–3]. Sixty minutes of ret-
inal ischemia was subsequently followed by the removal 
of the 30-gauge needle from the rat’s anterior chamber 
for the return of the blood supply, namely reperfusion. 
The control rats’ eyes received a sham procedure where 
the saline reservoir was not raised [3].
Drug administration
The rats were arbitrarily allocated into various Groups. A 
daily oral intake 3 mL of water (vehicle; Group 2), a low 
intake of CJDHW (Sun Ten Pharmaceutical Co., Taipei, 
Taiwan; 2.8  g/kg/day; CJDHW2.8; Group 3) or a high 
intake of CJDHW (4.2  g/kg/day; CJDHW4.2; Group 4) 
was given for 7 consecutive days either before (preis-
chemic drug administration) or after HIOP-induce reti-
nal ischemic injury (postischemic drug administration). 
The control rats’ eyes received a sham procedure (Group 
1) as mentioned above. Intravitreal injections were per-
formed by a 30-gauge needle attached to a 25 μL syringe 
after pupil dilation with 1  % tropicamide (Alcon, Inc., 
Puurs, Belgium) and 2.5  % phenylephrine (Akorn, Inc., 
IL, USA). In Group 5, intravitreal injections of 4  μL of 
0.5  mM SB203580 (p38 MAPK inhibitor; Calbiochem, 
San Diego, CA, USA) were performed on ischemic eyes 
15 min before pressure-induced retinal ischemia.
Flash ERG measurement
We recorded ERG data on all the animals pre-ischemia 
(day 0) followed by at 1, 3, 5, and 7 days post-ischemia and 
administration of the appropriate compounds. Dark adap-
tation for at least 8 h, anesthesia during the ERG record-
ings and pupil dilation with 1  % tropicamide and 2.5  % 
phenylephrine were performed on the rats [1, 2]. A stimu-
lus of 0.5 Hz was induced by placing a strobe 2 cm before 
the eye of each rat. We recorded 15 consecutive responses 
at 2-s intervals as well as 10  kHz; these responses were 
amplified and averaged as described previously [1, 2]. 
The b-wave reflects the function of the bipolar cells and 
the inner layers of the retina [20]. The b-wave ratio was 
calculated, which was the treated ischemic retina’s b-wave 
amplitude divided by the untreated contralateral normal 
retina’s b-wave amplitude [1, 2].
Hematoxylin and eosin staining
Following retinal ischemia plus 1 or 7  days of reperfu-
sion, the eyeballs were marked at the 12 o’clock position 
of the cornea with silk suture; they were then enucle-
ated and fixed in 4 % paraformaldehyde at 4°C for 24 h. 
After fixation, the anterior segment was removed, and 
the posterior eyeball containing the optic disc was dehy-
drated in a graded ethanol series and embedded in paraf-
fin. For hematoxylin and eosin (HE) stain [21, 22], 5 μm 
thick sections were taken along the vertical meridian and 
observed under a light microscope (Leica, Heidelberg, 
Germany).
To quantify the retinal ischemic injury, we meas-
ured various layer thicknesses. Mounted sections were 
microscopically observed and photographed at the same 
magnification (Ilford Pan-F plus film, 50 ASA) and the 
thickness of the various areas of the retina was measured 
from the photographs.
The overall retinal thicknesses (from the inner limit-
ing membrane to the RPE layer), the inner retinal thick-
ness [(from the inner limiting membrane to the inner 
nuclear layer (INL)], and the thickness of the inner plexi-
form layer (IPL) were measured. All measurements were 
carried out approximately 1000 μm from the optic disc. 
Three sections per eye were averaged. The various thick-
nesses were measured by research staff blinded to the 
source of the tissue to investigate any differences in the 
thickness between the four Groups (Groups 1, 2, 3 and 4).
Immunofluorescence analysis
After sacrifice, intracardial perfusion with normal saline 
(w/v) was given to the rats; the retinal sections were 
retrieved, soaked with 4  % (w/v) paraformaldehyde 
(Sigma-Aldrich, St. Louis, USA) for 45  min fixation and 
immersed in 30 % sucrose (Sigma-Aldrich, St. Louis, USA) 
for cryosection [1, 2]. Retinal sections were collected 1 
and 7  days following retinal ischemia with pre-adminis-
tration of CJDHW or vehicle, or following the sham pro-
cedure. Overnight, the retinal samples were incubated 
with primary antibodies: goat anti-ChAT polyclonal anti-
body, mouse anti-vimentin monoclonal antibody and rab-
bit anti-GFAP polyclonal antibody as described previously 
[1, 2]. Afterwards, the retinal samples were incubated 
with secondary antibody: rhodamine-conjugated rabbit 
anti-goat antibody, fluorescein isothiocyanate-conjugated 
goat anti-mouse IgG or FITC-conjugated goat anti-rabbit 
IgG as described previously. In parallel, the cellular nuclei 
were stained with 4,6-diamidine-2-phenylindole dihy-
drochloride as described previously. We utilized a fluo-
rescence microscope (Olympus BX-51, Olympus, Tokyo, 
Japan) to evaluate the retinal samples as described pre-
viously [1, 2]. When it is was necessary to compare the 
immunoreactivity in retinal tissues treated in different 
ways an independent scientist of the laboratory was asked 
to grade any changes by relating to the immunoreactivity 
in Group 1. In this way bias was avoided as far as possible. 
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For example, the enhanced vimentin/GFAP immunoreac-
tivity in Group 2 was alleviated by high dose of CJDHW 
as shown in Group 4.
Terminal deoxynucleotidyl‑transferase (TdT)‑mediated 
dUTP nick end‑labeling (TUNEL) assay
After I/R, the rats were sacrificed one and 7  days later 
and their eyes were removed for TUNEL staining (In 
situ Cell Death Detection Kit, Fluorescein; Roche; Man-
nheim, Germany) to investigate cell apoptosis [3]. The 
retinal samples were fixed with 10  % formaldehyde for 
24  h afterwards. The retinal samples were soaked with 
proteinase K (Sigma-Aldrich, St. Louis, USA) (25 μg/mL) 
followed by incubation in H2O2/methanol for 5  min at 
25°C to inactivate endogenous peroxidases. Negative and 
positive controls were measured as described previously 
[3]. After washing with Tris buffered saline, the retinal 
samples were soaked with a TdT enzyme/labeling reac-
tion mix at 37  °C for 90  min. This reaction was initial-
ized on the binding of digoxigenin-dUTP to the 3′-OH 
end of DNA by TdT, followed by incubation in an anti-
digoxigenin antibody conjugated with peroxidase. Upon 
termination of the labeling reaction in stop buffer with 
2× SSC (300  mM NaCl, 30  mM sodium citrate; Gene-
Copoeia, MD, USA), the retinal sections were processed 
in a standard streptavidin-horseradish peroxidase (HRP) 
reaction with 3,3′ diaminobenzidine (Sigma-Aldrich, St. 
Louis, USA) as the chromogenic peroxidase substrate, 
and counterstained with methyl green (Sigma-Aldrich, 
St. Louis, USA). The average number of TUNEL positive 
cells per field was counted as described previously [3].
Retrograde labeling of RGCs
After anesthesia, the rats were made a 2-cm incision 
in the scalp, and drilled two small holes into the skull 
as described previously [3]. Next, 2  μL of 5  % fluoro-
gold (Sigma-Aldrich, St. Louis, USA) were injected by 
a micropipette at depths of 3.8, 4.0, and 4.2  mm below 
the skull. Three days after retrograde immunolabeling 
of RGCs, HIOP was carried out on the right eyes of the 
animals whose fellow eyes served as the sham. The retina 
was gently retrieved, fixated, dissected and processed as 
described previously [3] The average RGC density was 
defined as the ratio of the total RGC number to the total 
retinal area evaluated [3].
Measurement of the concentrations of various retinal 
mRNAs
The retinal mRNA concentrations of Thy-1 and MMP-9 
were investigated by a real-time polymerase chain reac-
tion (PCR) technique [1, 23]. One day following retinal 
ischemia with either preadministration of mentioned 
compounds or following a sham procedure, the animals 
were sacrificed and the retinal samples were processed as 
described previously [1, 23]. Retinal RNA was extracted 
and first strand complementary DNA (cDNA) synthe-
sis was carried out on 2  µg deoxyribonuclease (DNase)-
treated RNA [1, 23]. The first-strand cDNA subsequently 
went on real-time PCR [1, 23]. The PCR and cycling were 
performed as instructed previously [1, 23]. Relative quanti-
tation was carried out utilizing β-actin as the internal con-
trol. This procedure normalized the measurement of the 
mRNA target (Ct) and took into consideration the altera-
tions in the quantity of total RNA applied to each reaction 
(Ct). The relative Thy-1/MMP-9 amount differences were 
measured as fold alterations correspondent to the control 
in regards to the calibrator (Ct). Relative measurement of 
mRNA level was based on the formula of 2−Ct as stated [1, 
23]. The PCR reagents, software and machine were bought 
from AB Applied Biosystems. The results collected were 
compared for each management, and a total percentage 
alteration correspondent to the control was measured. 
As outlined in Table 1, the following PCR oligonucleotide 
primers (β-actin, Thy-1 and MMP-9) were purchased at 
Mission Biotech Co., Ltd. (Taipei, Taiwan).
Western blotting assay
One day after treatment of retinal ischemia with pre-
administration of relevant compounds or following a 
sham procedure, the animals were sacrificed. Retinal sam-
ples were retrieved and sonicated by a sonicator (Misonix 
XL-2000, Misonix, NY, USA) in a lysis buffer (25  mM 
bicine, 150  mM sodium chloride; pH 7.6), mammalian 
protein extraction reagent (Thermo Scientific, Rockford, 
lL 61105 USA). Equal amounts of denatured proteins 
(30 μg/20 μL/well) were processed on a sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE; 
Bio-Rad, Hercules, CA, USA) as described previously [23, 
24]. The nitrocellulose blots (NC) were next soaked 12 h 
at 4  °C with various primary antibodies: mouse mono-
clonal [AC-15] anti-β-actin antibody (1:5000; Abcam 
Inc., Cambridge, UK), rabbit monoclonal antibody Bcl-2 
(50E3; 1:1000; Cell Signaling, Danvers, MA 01923, USA), 
mouse monoclonal antibody HO-1 (ab 13248) (1:1000; 
Abcam Inc., Cambridge, UK), mouse monoclonal anti-
body P-p38 MAPK (1:1000; Cell Signaling, Danvers, MA 
01923, USA), rabbit monoclonal antibody p38 MAPK 
(1:1000; Cell Signaling, Danvers, MA 01923, USA) and 
rabbit monoclonal antibody MMP-9 (EP1255Y; 1:1000; 
Abcam Inc., Cambridge, UK). The blots were soaked with 
relevant secondary antibody, HRP-conjugated goat anti-
rabbit or anti-mouse IgG (1:5000 or 1:2000; Amersham, 
UK) at 37  °C for 1 h. Finally, the membranes were then 
developed, and exposed as described previously [23, 24], 
and then scanning densitometry was utilized to evaluate 
the level of each protein.
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Gel zymography
Protein samples were prepared in a similar manner to 
that described for the Western blotting analysis; these 
samples were then loaded onto and separated by 10  % 
Tris–glycine gel [1.5 M Tris–Cl 2.5 mL, pH 8.8 (Sigma-
Aldrich, St. Louis, USA); 10  % (w/v) sodium dodecyl 
sulfate 0.1  ml (Sigma-Aldrich, St. Louis, USA); 40  % 
polyacryamide. 2.475  mL (Merck KGaA, Darmstadt, 
Germany); 10  % (w/v) ammonium persulfate 0.1  mL 
(Sigma-Aldrich, St. Louis, USA); N,N,N’,N’ tetramethy-
lethylenediamine 0.01  mL (J.T.Baker Inc., Phillipsburg, 
NJ, USA); Sterile deionised water 4.625 mL)] with 0.1 % 
gelatin (Sigma-Aldrich, St. Louis, USA) as protease sub-
strate [25]. After separation by electrophoresis, the gel 
was incubated in renaturation buffer (2.7 % Triton X-100 
in distilled water) at room temperature with gentle shak-
ing for 30  min. The renaturation buffer was discarded 
and replaced with developing buffer (50  mmol/L Tris 
Base, 40  mmol/L HCl, 200  mmol/L NaCl, 5  mmol/L 
CaCl2, 0.2  % Brij 35). After 30  min equilibration by 
the developing buffer, the gel was incubated with fresh 
developing buffer at 37  °C for 48  h. After being devel-
oped, the gel was stained with 0.5  % Coomassie Blue 
R-250 (J.T.Baker Inc., Phillipsburg, NJ, USA) for 30 min 
and then destained appropriately. The visualized bands 
were then analyzed by scanning densitometry (software: 
ImageJ Version 1.48, NIH, USA).
Statistical analysis
Three or more Groups were compared by one-way 
analysis of variance (ANOVA; SigmaPlot Version 12.5, 
Systat Software Inc., California, USA). The Tukey mul-
tiple-comparison test was performed to compare the 
control column (i.e., vehicle-treated ischemic retinas) 
to other columns (i.e., CJDHW-treated ischemic reti-
nas). The results were represented as mean  ±  SD. P 
values less than 0.05 were considered statistically signif-
icant. The dose–response relationship was determined 
visually.
Results
The effect of CJDHW on the amplitude or the ratio of the 
b‑wave
In the sham retina (Fig.  1a), the ERG b-wave was deter-
mined to be 0.98  mV. However, retinal ischemia plus 
1 day of reperfusion led to a considerable decrease in the 
amplitude of the b-wave to 0.11  mV. Notably, pretreat-
ing rats with CJDHW (Groups 3 and 4) counteracted this 
ischemia-induced decrease in the amplitude of the b-wave 
in a dose-dependent manner, with the amplitude of the 
b-wave increasing to 0.26 and 0.39 mV, respectively, 1 day 
after I/R. As shown in Fig. 1b (n = 5), administering I/R 
following the rats’ pretreatment with the vehicle (Group 
1) led to a significant (P < 0.001) decrease in the b-wave 
ratio on I/R days 1, 3, 5 and 7 compared with the preis-
chemic b-wave ratio (day 0: 0.95 ± 0.05; day 1: 0.44 ± 0.07; 
day 3: 0.44 ± 0.05; day 5: 0.38 ± 0.04; day 7: 0.38 ± 0.04). 
Pretreating rats with CJDHW (Group 3 vs. 4) led to a sig-
nificant (P < 0.001; at 2.8 and 4.2 g/kg/day) dose-depend-
ent decrease in the ischemia-induced b-wave ratio on I/R 
day 1 (0.66 ± 0.07 vs. 0.72 ± 0.07), day 3 (0.70 ± 0.05 vs. 
0.78 ± 0.04), day 5 (0.70 ± 0.03 vs. 0.80 ± 0.04) and day 
7 (0.69  ±  0.07 vs. 0.81  ±  0.03) after ischemia. Moreo-
ver, the preischemic b-wave ratio (day 0) was recorded at 
0.99 ± 0.12 vs. 0.93 ± 0.10 (P = 0.391; Group 3 vs. 4).
Furthermore, there was a significant (P  =  0.003; 
n =  5) decrease in the b-wave ratio (0.43 ±  0.02) com-
pared with the preischemic b-wave ratio (baseline at 
day 0: 1.04 ± 0.07) 7 days after I/R and the postischemic 
administration of vehicle (Group 2). In contrast, there 
was a significant dose-dependent improvement in the 
ischemia-induced b-wave ratio reduction (0.56 ± 0.23 vs. 
0.63 ± 0.09; P < 0.001) 7 days after I/R and the postisch-
emic administration of CJDHW (Group 3 vs. 4). Notably, 
in Group 1, comparing the ERG b-wave ratios (the sham 
eye’s b-wave amplitude divided by the untreated fellow 
normal eye’s one) revealed that there were no significant 
differences between the pre-sham ERG b-wave ratio (day 
0) and the post-sham values (day 1, 3, 5 or 7).
Table 1 Sequences of oligonucleotide primers and details of polymerase chain reactions
F forward; R reverse
mRNA Primers (5′→3′) Bases in base pairs Product size Cycles profile Cycles number
Denaturation/annealing/ 
extension (temperature  
and time in seconds)
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The effect of CJDHW on the thickness of the various retinal 
layers stained by HE
Figure 2 and Table 2 show details of the retinal sections 
collected from a similar eccentricity (1 mm from disc) for 
the four different Groups (n = 4–6). Compared with the 
samples collected from the Group 1 (sham 1 day, Fig. 2a, 
e: 174.12 ±  3.64  μm for whole retina, 41.68 ±  2.69 μm 
for INL, 41.93 ±  1.58  μm for IPL; sham 7  days, Fig.  2f, 
j: 180.25  ±  4.35  μm for whole retina, 38.10  ±  1.39  μm 
for INL, 38.38  ±  1.43 for IPL) following ischemia 
plus 1 and 7  days of reperfusion (I/R) and pretreat-
ing rats with vehicle [Group 2 on I/R day 1 (Fig.  2b, e) 
vs. day 7 (Fig. 2g, j)], the INL (P = 0.0483 vs. P = 0.004; 
37.13  ±  5.04 vs. 24.74  ±  3.60 μm), IPL (P  =  0.003 
vs. P  <  0.001; 36.81  ±  2.21 vs. 20.34  ±  1.79 μm) and 
whole retina (P =  0.005 vs. P =  0.03; 165.43 ±  4.44 vs. 
141.02 ±  9.47 μm) samples showed a significant reduc-
tion in their thickness. Treating animals with 2.8  g/kg/
day of CJDHW resulted in a small dose-dependent effect 
against retinal ischemia following 1 day (Group 3, Fig. 2c, 
e: 168.45 ± 12.89 μm for the whole retina with P = 0.67, 
37.52 ± 2.09 for the INL with P = 0.89, 37.16 ± 4.55 for 
the IPL with P =  0.89) or 7 days of reperfusion (Group 
3, Fig.  2h, j: 156.18  ±  7.92  μm for the whole retina 
with P =  0.04, 29.23 ±  5.43 for the INL with P =  0.18, 
26.20 ± 3.60 for the IPL with P = 0.01). In contrast, the 
use of a larger dose of 4.2 g/kg/day of CJDHW led to a 
significant reduction in the effect of ischemia plus 1 day 
(Group 4, Fig. 2d, e: 172.00 ±  1.57 μm for whole retina 
with P  =  0.045, 39.74  ±  3.13 for INL with P  =  0.047, 
40.39 ± 0.86 for IPL with P = 0.042) or 7 days of reperfu-
sion (Group 4, Fig. 2i, j: 171.78 ± 10.38 μm for whole ret-
ina with P = 0.002, 34.45 ± 4.02 for INL with P = 0.007, 
33.53 ± 1.85 for IPL with P < 0.001). Ischemia pretreated 
with vehicle (Group 2) led to a significant reduction 
in the thickness of the inner retinal layers (INL +  IPL; 
45.08  ±  2.85  μm; P  <  0.001) compared with the sham 
(Group 1; 76.48  ±  1.72  μm) on day 7 after ischemia. 
Notably, this reduction in the thickness was attenu-
ated in a dose-dependent manner by CJDHW (P = 0.03, 
55.38 ± 7.57 μm in Group 3; P < 0.001, 67.98 ± 5.48 μm 
in Group 4).
The effect of CJDHW on ChAT immunolabeling
Figure  3 and Table  3 (n  =  6) showed the relation-
ships between the ChAT (red) immunolabeling and 
the amacrine cell bodies (short arrows; sham 1  day, 
Fig. 3a, e: 34.33 ± 6.59 cells/field; sham 7 days, Fig. 3f, j: 
36.83 ± 6.68 cells/field) in the inner nuclear layer (INL) 
and the ganglion cell layer on days 1 and 7 after the sham 
procedure (Group 1). Moreover, the neuronal processes 
in these animals demonstrated two well-delineated 
a b
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Fig. 1 Electroretinogram (ERG): The effect of CJDHW on retinal ischemia plus reperfusion (I/R). a There was a considerable reduction in the ampli‑
tude of the ERG b‑wave following pressure‑induced retinal ischemia plus reperfusion (I/R) and pretreatment with vehicle in a representative animal 
of the I/R + Vehicle (Group 2) compared with the sham procedure retina (Group 1). Pretreatment with CJDHW (at 2.8 g/kg/day, I/R + CJDHW2.8, 
Group 3; at 4.2 g/kg/day, I/R + CJDHW4.2, Group 4) led to a dose‑dependent attenuation in this reduction in one rat from each defined Group. b 
In contrast with the Group 1, there was a significant (**P < 0.01) decrease in the b‑wave ratio in the Group 2 1, 3, 5 and 7 days following ischemia. 
Dose‑dependent and significant (††P < 0.01) attenuation of this ischemia‑induced decrease was achieved after pretreating rats with 2.8 g/kg/day 
(Group 3) and 4.2 g/kg/day of CJDHW (Group 4). These results are expressed as the mean ± SD (n = 5). CJDHW Chi‑Ju‑Di‑Huang‑Wan
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Fig. 2 The thicknesses of various retinal layers. This figure shows sections of retina from approximately the same eccentricity. (a sham 1 day) and 
(f sham 7 days) show sections of Group 1 1 day and 7 days following the sham procedure, respectively. Pictures b and g respectively show retinas 
that received ischemia plus reperfusion (I/R) for 1 day (I/R 1 day + Vehicle) or 7 days and pretreatment of vehicle (I/R 7 days + vehicle; Group 2). 
Compared with the Group 1 (a, f), the thickness of the inner retina [INL inner nuclear layer, IPL inner plexiform layer and ganglion cell layer] in the 
ischemic retina pretreated with vehicle (Group 2; b, g) was reduced considerably. This reduction in the thickness of the inner retinal layers was 
attenuated in animals given I/R for 1 or 7 days and pretreated with 2.8 g/kg/day [Group 3; on I/R day 1, (c) on I/R day 7, (h)] and 4.2 g/kg/day of 
CJDHW [Group 4; on I/R day 1, (d) on I/R day 7, (i)]. Scale bar = 50 μm. Morphometric analysis of the thicknesses of various retinal layers from sec‑
tions of similar eccentricity (e, j). Compared with the Group 1 (sham 1 day; sham 7 days), the thicknesses of the whole retinal layer, INL and IPL were 
significantly reduced in the vehicle‑treated ischemic retinas (Group 2). Moreover, these reductions were attenuated in a dose‑dependent manner 
when the ischemic retinas were pretreated with 2.8 (Group 3) and 4.2 g/kg/day of CJDHW (Group 4). Results are the mean ± SD of the number of 
experiments (n = 4–6). *or **significantly different (P < 0.05 or P < 0.01) from the Group 1. † or ††significantly different (P < 0.05 or P < 0.01) from the 
Group 2 on I/R day 1 or 7. Total whole retina, CJDHW Chi‑Ju‑Di‑Huang‑Wan
Table 2 Hematoxylin and eosin staining
In comparison of the control retina, 1 or 7 days following sham procedure (Group 1; Sham 1 day, n = 6; Sham 7 days, n = 6), after retinal ischemia plus 1 or 7 days of 
reperfusion and pretreatment with vehicle (Group 2; I/R 1 day + vehicle, n = 4; I/R 7 days + vehicle, n = 5), there was a significant decrease (* P < 0.05; ** P < 0.01) in 
the thickness of the whole retina, the INL and the IPL. In contrast, this significant decrease was dose-dependently (with a less effect at 2.8 g/kg/day, I/R + CJDHW2.8, 
Group 3, n = 4) and significantly († P < 0.05; †† P < 0.01; Group 3; I/R + CJDHW4.2, Group 4, n = 4) inhibited by pretreatment with CJDHW. The results are the 
mean ± SD (μm)
CJDHW4.2 Chi-Ju-Di-Huang-Wan at 4.2 g/kg/day, INL inner nuclear layer, IPL inner plexiform layer
Group 1 2 3 4
Retinal thickness on day 1
 Whole 174.12 ± 3.64 165.43 ± 4.44** 168.45 ± 12.89 172.00 ± 1.57†
 INL 41.68 ± 2.69 37.13 ± 5.04* 37.52 ± 2.09 39.74 ± 3.13†
 IPL 41.93 ± 1.58 36.81 ± 2.21** 37.16 ± 4.55 40.39 ± 0.86†
Retinal thickness on day 7
 Whole 180.25 ± 4.35 141.02 ± 9.47** 156.18 ± 7.92† 171.78 ± 10.38††
 INL 38.10 ± 1.39 24.74 ± 3.60** 29.23 ± 5.43 34.45 ± 4.02†
 IPL 38.38 ± 1.43 20.34 ± 1.79** 26.20 ± 3.60† 33.53 ± 1.85†
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bands in the inner plexiform layer (IPL; long arrows), 
which was consistent with previous reports [1, 23]. In the 
ischemic retina pretreated with the vehicle, the immu-
nolabeled amacrine cell bodies (Group 2 on I/R 1  day, 
Fig. 3b, e: 12.67 ± 2.80 cells/field; Group 2 on I/R 7 day, 
Fig. 3g, j: 13.17 ± 4.07 cells/field) were significantly less 
numerous (P  <  0.001) following retinal ischemia plus 1 
and 7 days of reperfusion. Furthermore, there was a sig-
nificant decrease in the IPL immunoreactivity of these 
cells. The ischemic activity was therefore inhibited in a 
dose-dependent manner after pretreating rats with a 
low (Group 3 on I/R day 1, Fig. 3c, e: 28.33 ± 2.16 cells/
field with P  <  0.001; Group 3 on I/R day 7, Fig.  3h, j: 
23.50 ±  3.45  cells/field with P  <  0.001) or high dose of 
CJDHW (Group 4 on I/R day 1, Fig. 3d, e: 31.67 ± 3.88 
cells/field with P < 0.001; Group 4 on I/R day 7, Fig. 3i, j: 
28.50 ± 4.59 cells/field with P < 0.001).
The effect of CJDHW on vimentin or GFAP 
immunoreactivity
As shown in Fig. 4, the immunolabeling of the vimentin 
found in the Müller cell processes extended from the 
end foot of these cells to the IPL, as well as progress-
ing into the INL and the outer nuclear layer, which was 
consistent with previous reports [1, 16]. Anti-vimen-
tin immunolabeling was found to be enhanced 1 and 
7  days after I/R and pretreating rats with the vehicle 
(Group 2 on I/R day 1, Fig.  4c; Group 2 on I/R day 7, 
Fig. 4l). Nevertheless, the ischemic effect was alleviated 
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Fig. 3 Choline acetyltransferase (ChAT; red) immunohistochemistry. Amacrine cell bodies (short arrows) were located in the INLs and ganglion 
cell layers of the retinas subjected to the sham procedure (Group 1) for 1 day (a; sham 1 day) and 7 days (f; sham 7 day); the neuronal processes 
displayed two well‑delineated bands (long arrows) in the inner plexiform layer (IPL). Retinal ischemia plus reperfusion (I/R) for 1 or 7 days led to a 
considerable reduction in the ChAT immunolabeling of the IPLs as well as the number of ChAT immunolabeled amacrine cell bodies; the pretreat‑
ment with the vehicle had no influence on the defined ischemic changes [Group 2; on I/R day 1, (b) on I/R day 7, (g)]. However, these ischemic 
alterations were clearly alleviated after pretreating the rats with 2.8 g/kg/day [Group 3; on I/R day 1, (c); on I/R day 7, (h)] and 4.2 g/kg/day of CJDHW 
[Group 4; on I/R day 1, (d); on I/R day 7, (i)]. The ChAT immunolabeled images were merged with those obtained for 4,6‑diamidine‑2‑phenylindole 
dihydrochloride staining [DAPI blue; (a–d, f–i)]. Each bar represents the mean ± SD (n = 6) 1 day (e) and 7 days following the sham procedure or I/R 
(j). *represents significance (P < 0.05; Group 1 vs. 2 on I/R day 1 or 7). †represents significance (P < 0.05; Group 2 vs. 3 or Group 4 on I/R day 1 or 7). 
CJDHW Chi‑Ju‑Di‑Huang‑Wan. Scale bar = 35 μm
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Table 3 Choline acetyltransferase (ChAT) immunolabelling
In comparison of the control retina, 1 or 7 days following sham procedure (Sham; Group 1), after retinal ischemia plus 1 or 7 days of reperfusion and pretreatment 
with vehicle (I/R + vehicle; Group 2), the number of CHAT-immunolabeling amacrine cells per field was significantly decreased (* P < 0.05) in the inner nuclear layer 
and the ganglion cell layer. In contrast, this significant decrease was dose-dependently (with a less effect at 2.8 g/kg/day, I/R + CJDHW2.8, Group 3) and significantly 
(† P < 0.05; Group 3; I/R + CJDHW4.2, Group 4) inhibited by pretreatment with CJDHW. The results are the mean ± SD (n = 6)
Group 1 2 3 4
Cholinergic amacrines (number/field) on day 1 34.33 ± 6.59 12.67 ± 2.80* 28.33 ± 2.16† 31.67 ± 3.88†




























































Fig. 4 Vimentin immunohistochemistry. One (b) or 7 days following the sham procedure (k; Group 1), the Müller cells were demonstrated with 
vimentin (green) immunolabeling at the end feet (arrow heads) in the ganglion cell layer (GCL) and at the processes in the IPL inner plexiform layer 
(arrows), INL inner nuclear layer and ONL outer nuclear layer. In contrast with the Group 1, anti‑vimentin immunolabeling was increased one or 
7 days after ischemia plus reperfusion (I/R) with preadministration of vehicle [Group 2; on I/R day 1, (c); on I/R day 7, (l)]. This enhancement was 
attenuated by pretreatment with 2.8 g/kg/day [Group 3; on I/R day 1, (d) on I/R day 7, (m)] or 4.2 g/Kg/day of CJDHW [Group 4; on I/R day 1, (e); on 
I/R day 7, (n)]. The cellular nuclei of the Group 1 (a, j) were immunolabeled with 4,6‑diamidine‑2‑phenylindole dihydrochloride (DAPI; blue). GFAP 
immunohistochemistry. In contrast with the Group 1, one (f) or 7 days following the sham procedure (o), anti‑GFAP immunolabeling was also 
increased 1 (g) or 7 days day after ischemia plus reperfusion (I/R) with preadministered vehicle (p, Group 2). This enhancement was blunted by 
pretreatment with 2.8 g/kg/day (Group 3; on I/R day 1, H; on I/R day 7, q) or 4.2 g/kg/day of CJDHW (Group 4; on I/R day 1, I; on I/R day 7, r). GFAP, 
glial fibrillary acidic protein; CJDHW Chi‑Ju‑Di‑Huang‑Wan. Scale bar = 25 μm
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Fig. 4d; Group 3 on I/R day 7, Fig. 4m) or high dose of 
CJDHW (Group 4 on I/R day 1, Fig. 4e; Group 4 on I/R 
day 7, Fig. 4n). DAPI (blue; Fig. 4a, j) was used to stain 
the nuclei in the normal control cells.
Anti-GFAP immunoreactivity was also enhanced 1 
and 7 days after retinal ischemia in the rats pretreated 
with vehicle (Group 2 on I/R day 1, Fig. 4g; Group 2 on 
I/R day 7, Fig. 4p) compared with those in the control 
retina Group (sham 1 day, Fig. 4f; sham 7 days, Fig. 4o). 
However, this enhancement was nullified by pretreat-
ing the rats with a low (Group 3 on I/R day 1, Fig. 4h; 
Group 3 on I/R day 7, Fig. 4q) or high dose of CJDHW 
(Group 4 on I/R day 1, Fig.  4i; Group 4 on I/R day 7, 
Fig. 4r).
The effect of CJDHW on the presence of apoptotic cells 
in the RGC layer
In contrast to the control retina 1 or 7 days after the sham 
procedure (Group 1 on days 1 and 7: no TUNEL-positive 
cells), ischemic rats pretreated with vehicle showed a sig-
nificant (P = 0.008 on I/R days 1 and 7) increase in the 
number of TUNEL-positive cells in the RGC layer (Group 
2; on I/R day 1: 1.40  ±  0.55  cells/field; on I/R day 7: 
1.40 ± 0.55 cells/field), as shown in Table 4 (n = 5). This 
increase in the number of TUNEL-positive cells was alle-
viated in a dose-dependent (with a small effect at 2.8 g/
kg/day; Group 3; on I/R day 1: 0.80  ±  0.45  cells/field, 
P =  0.09; on I/R day 7: 0.80 ±  0.84 cells/field, P =  0.2) 
and significant (at 4.2 g/kg/day) manner 1 or 7 days after 
ischemia after pretreating the rats with CJDHW (Group 
4; on I/R day 1: 0.40 ± 0.55 cells/field, P = 0.02; on I/R 
day 7: 0.60 ± 0.55 cells/field, P = 0.0497).
Retrograde fluorogold immunolabeling of RGCs
As shown in Fig.  5 and Table  5 (n  =  3), the RGC 
densities were 1952.16  ±  125.29 (sham 1  day) and 
1737.23 ±  151.94 cells/mm2 (sham 7 day) 1 and 7 days 
after the sham procedure (Group 1). In contrast, the 
RGC densities 1 and 7  days after retinal ischemia 
pretreated with vehicle decreased significantly to 
929.01 ± 135.00 (Group 2 on I/R day 1; P < 0.001) and 
887.73  ±  158.18 (Group 2 on I/R day 7; P  =  0.003), 
respectively. Notably, this decrease was alleviated in 
a dose-dependent manner (with a small effect at 2.8  g/
kg/day; Group 3 on I/R day 1: 1112.65  ±  164.10 cells/
mm2, P =  0.21; Group 3 on I/R day 7: 941.89 ±  38.91, 
P =  0.60). The extent of this alleviation effect was sig-
nificantly and much more pronounced after pretreating 
rats with a high dose of CJDHW (Group 4 on I/R day 
1: 1691.36 ±  237.57, P =  0.008; Group 4 on I/R day 7: 
1389.02 ± 53.20, P = 0.007).
The effect of CJDHW on the retinal mRNA concentrations 
of Thy‑1 and MMP‑9
As shown in Fig. 6 and Table 6 (n = 5 for Thy-1; n = 3–4 
for MMP-9), there were significant differences in the 
ratios of Thy-1 (0.31  ±  0.15; P  =  0.006) and MMP-9 
(4.44  ±  0.84; P  =  0.003) in the vehicle-pretreated 
ischemic retina samples 24 h after retinal ischemia com-
pared with the control sham retina (Group 1; Thy-1: 
0.99  ±  0.38; MMP-9: 0.75 ±  0.55). Compared with the 
vehicle-pretreated ischemic retina samples (Group 2), the 
ischemic rats pretreated with CJDHW showed a dose-
dependent (Group 3; with a small effect at 2.8 g/kg/day; 
Thy-1: 0.45±0.20; MMP-9: 3.01±1.90) and significant 
(Group 4; at 4.2 g/kg/day) decrease in the overexpression 
of MMP-9 (1.13 ±  0.34; P =  0.03). This effect was also 
coupled by a significant (Group 4; at 4.2 g/kg/day) coun-
teraction in the underexpression of Thy-1 (0.78 ±  0.32; 
P = 0.02).
The effect of CJDHW on the levels of in vivo retinal proteins
As shown in Fig.  7 and Table  7 (n  =  4–9 for Bcl-2; 
n = 4 for HO-1; n = 4–9 for P-p38 MAPK; n = 4–5 for 
MMP-9), retinal ischemia plus 24  h of reperfusion and 
pretreatment with vehicle (Group 2) led to a signifi-
cant decrease in the Bcl-2 ratio (0.78 ±  0.08; P =  0.03) 
or increase in HO-1 (0.99  ±  0.20; P  =  0.008), P-p38 
MAPK (1.12 ± 0.18; P = 0.03) and MMP-9 (0.70 ± 0.23; 
P = 0.02) ratios compared with the control sham retina 
(Group 1; Bcl-2: 1.06 ±  0.25; HO-1: 0.27 ±  0.12; P-p38 
MAPK: 0.15 ± 0.06; MMP-9: 0.25 ± 0.26) 24 h after the 
sham procedure. However, these changes underwent 
dose-dependent (with a small effect at 2.8  g/Kg/day of 
CJDHW; Group 3; Bcl-2: 0.83±0.11; HO-1: 1.46 ± 0.99; 
P-p-38 MAPK: 0.83 ± 0.21; MMP-9: 0.44 ± 0.15) and sig-
nificant changes after pretreating rats with 4.2  g/kg/day 
of CJDHW (Group 4; Bcl-2: 1.80 ± 0.34, P = 0.001; P-p38 
MAPK: 0.57  ±  0.18, P  <  0.001; MMP-9: 0.39  ±  0.10, 
P = 0.02) and/or a 2 nmole solution of SB203580 (Group 
5; p38 MAPK inhibitor; MMP-9: 0.21 ± 0.07, P = 0.002; 
P-p38 MAPK: 0.18 ±  0.07, P  <  0.001), as well as a sig-
nificant increase in the expression of HO-1 (4.15 ± 2.08; 
Table 4 Terminal deoxynucleotidyl-transferase dUTP nick 
end-labeling (TUNEL)
No TUNEL-positive apoptotic cell was observed 1 or 7 days after the sham 
procedure (Sham; Group 1). After retinal ischemia plus 1 or 7 days of reperfusion 
and pretreatment with vehicle (I/R + vehicle; Group 2), the number of apoptotic 
cells was significantly (** P < 0.01) increased in the retinal ganglion cell layer. 
In contrast, this significant increase was dose-dependently (with a less effect 
at 2.8 g/kg/day, I/R + CJDHW2.8; Group 3) and significantly († P < 0.05; at 4.2 g/
kg/day, I/R + CJDHW4.2; Group 4) inhibited by pretreatment with CJDHW. The 
results are the mean ± SD (n = 5)
Group 1 2 3 4
Apoptotic cell No. on day 1 0 1.40 ± 0.55** 0.80 ± 0.45 0.40 ± 0.55†
Apoptotic cell No. on day 7 0 1.40 ± 0.55** 0.80 ± 0.84 0.60 ± 0.55†
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P = 0.03) in Group 4. Notwithstanding the changes listed 
above, the total p38 protein levels in the retina were 
unchanged across all of the different Groups.
The MMP-9 activities in the retina samples collected 
from the different Groups were detected by zymography 
(Fig. 8; Table 8; n = 4–5). The results revealed that there 
was a significant (P < 0.001; 5.03 ± 1.57) increase in the 
MMP-9 activity in the vehicle-pretreated ischemic retina 
samples (Group 2) 24 h after ischemia compared with the 
sham procedure control retina (Group 1). However, the 
ischemic rats pretreated with CJDHW or SB203580 (p38 
MAPK inhibitor) demonstrated a dose-dependent (with 
a significant but smaller effect at Group 3; 3.05  ±  0.88; 
P = 0.03) and significant (Group 4: 1.59 ± 0.47; P = 0.002; 
Group 5: 1. 35  ±  0.41; P  =  0.001) decrease in MMP-9 
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Fig. 5 Fluorogold‑labeling. The microscopic images show the density of retinal ganglion cells (RGCs) a and 7 days after the sham‑procedure (f; 
Group 1), or b and 7 days of reperfusion following ischemia (I/R) with preadministered vehicle (g; Group 2) or Chi‑Ju‑Di‑Huang‑Wan at 2.8 g/kg/day 
(Group 3; on I/R day 1, c; on I/R day 7, h) and at 4.2 g/kg/day (Group 4; on I/R day 1, d; on I/R day 7, i). Each bar indicates the mean ± SD (e; j; n = 3). 
**indicates significant difference (P < 0.01; Group 1 vs. 2 on I/R day 1 or 7); †indicates significant difference (P < 0.05; Group 2 vs. 4 on I/R day 1 or 7). 
Scale bars = 25 μm
Table 5 Fluorogold immunolabeling
In comparison of the control retina, 1 or 7 days following sham procedure (Sham; Group 1), after retinal ischemia plus 1 or 7 days of reperfusion and pretreatment 
with vehicle (I/R + Vehicle; Group 2), the number of fluorogold-immunolabeling retinal ganglion cells (RGCs) per field was significantly decreased (** P < 0.01). In 
contrast, this significant decrease was dose-dependently (with a less effect at 2.8 g/kg/day, I/R + CJDHW2.8; Group 3) and significantly (†† P < 0.01; at 4.2 g/kg/day, 
I/R + CJDHW4.2; Group 4) inhibited by pretreatment with CJDHW. The results are the mean ± SD (μm; n = 3)
Group 1 2 3 4
RGCs (number/mm2) On day 1 1952.16 ± 125.29 929.01 ± 135.00** 1112.65 ± 164.10 1691.36 ± 237.57††
RGCs (number/mm2) On day 7 1737.23 ± 151.94 887.73 ± 158.18** 941.89 ± 38.91 1389.02 ± 53.20††
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Discussion
Vimentin and GFAP immunoreactivity were enhanced 
in Müller cells 1 and 7  days after I/R [1, 23], and this 
result was confirmed in the current study (Fig.  4c/g, 
l/p). Functionally compromised Müller cells exhibited a 
pronounced effect on the normal ERG b-wave [1, 2, 23], 
as shown in the current study (Fig.  1). In the ischemic 
retinas pretreated with vehicle, the observed increase 
in vimentin/GFAP immunolabeling coincided with a 
decrease in the amplitude of the b-wave. Notably, these 
ischemic changes were alleviated after pretreating the 
rats with CJDHW.
After retinal ischemia/reperfusion, the glutamatergic 
neurons (i.e., RGCs and amacrines) in the inner retina 
become susceptible to damage [1, 2, 9, 23], as shown in 
the current study. The number of cholinergic amacrines 
decreased following ischemia plus 1 or 7  days of reper-
fusion and pretreating the rats with the vehicle (Fig. 3b/e 
or g/j). The RGCs became dysfunctional following the 
disruption of the cholinergic signaling pathways in laser 
ablated retina [9]. The ischemic insult provided in the 
current study led to pronounced changes in the RGCs 
and amacrine cells, as evidenced by changes in the Thy-1 
mRNA levels (Fig. 6; Table 6), RGC fluorogold retrograde 
labeling (Fig. 5) and ChAT immunoreactivity (Fig. 3). The 
synapses between starburst amacrine cells and direction-
selective RGCs are essential to their functionality [26]. 
The ischemia induced reductions in ChAT immuno-
reactivity (Fig.  3d/e, i/j), the number of the fluorogold 
immunolabeled RGCs (Fig.  5d/e, i/j; Table  5) and the 
expression level of Thy-1 mRNA (Fig. 6a; Table 6) there-
fore provide clear and significant evidence of the blunting 
effect of pretreating ischemic rats with CJDHW.
After I/R, the ischemic retinas pretreated with the 
vehicle contained fewer RGCs (indexed by Thy-1 
mRNA) in the RGC layer (Fig.  6a; Table  6) compared 
with the sham retinas (Fig.  6; Table  4), along with 
numerous apoptotic cells in the RGC layer (Table  4). 
The ischemic retinas pretreated with CJDHW contained 
significantly more RGCs (Fig.  6a; Table  6) and signifi-
cantly fewer apoptotic cells in their RGC layer than the 
ischemic retinas pretreated with the vehicle (Table  4). 
The protective effect of CJDHW on retinal cells could 








































































Fig. 6 The mRNA expression levels of Thy‑1 (a), MMP‑9 (b) and β‑actin. Total mRNA was extracted and isolated from the sham procedure retinas 
(Group 1) or the ischemic retinas preadministered with vehicle (Group 2), or low (2.8 g/Kg/day; Group 3)/high dose (4.2 g/kg/day) of CJDHW (Group 
4). We evaluated the effect of each defined compound on the mRNA concentrations of Thy‑1 or MMP‑9 divided by the mRNA levels of β‑actin. 
**represents significance (P < 0.01; Group 1 vs. 2). † or ††represents significance for Thy‑1 (P < 0.05; Group 2 vs. 4) or MMP‑9 (P < 0.01; Group 2 vs. 4), 
respectively. The findings are presented as the mean ± SD (Thy‑1, n = 5; MMP‑9, n = 3–4)
Table 6 The ratios of  mRNA expression levels of Thy-1 or 
MMP-9 to that of β-actin
In retinal ischemia plus 24 h of reperfusion (I/R), total mRNA was extracted and 
isolated from the sham procedure retinas (Group 1) or the ischemic retinas 
preadministered with vehicle (Group 2), or low (2.8 g/kg/day; Group 3)/high 
dose (4.2 g/kg/day) of CJDHW (Group 4)
CJDHW Chi-Ju-Di-Huang-Wan
** represents significance (P < 0.01; Group 1 vs. 2)
†  or †† represents significance for Thy-1 (P < 0.05) or significance for MMP-9 
(P < 0.01; Group 2 vs. 4), respectively. The findings are presented as the 
mean ± SD (Thy-1, n = 5; MMP-9, n = 3–4)
Group 1 2 3 4
Thy‑1/β‑actin 
(n = 5)
0.99 ± 0.38 0.31 ± 0.15** 0.45 ± 0.20 0.78 ± 0.32†
MMP‑9/β‑actin 
(n = 3–4)
0.75 ± 0.55 4.44 ± 0.84** 3.01 ± 1.90 1.13 ± 0.34††
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the apoptotic pathway. This possibility is also supported 
by the observation that pretreating ischemic rats with 
CJDHW led to a significant increase in the expression 
of the Bcl-2 protein (Fig. 7; Table 7). To our knowledge, 
this study is the first reported account of CJDHW as a 
protective agent against retinal ischemic injury. CJDHW 
could preserve the electrophysiological functions of the 
retina, counteracting any reduction in the thickness of 
the inner retina and avoiding cholinergic neuron death. 
CJDHW achieves these protective effects by attenuating 
Müller cell vimentin/GFAP glial activation, decreasing 
the number of apoptotic cells in the RGC layer as well 
as by attenuating the downregulation of Thy-1 mRNA 
expression and reducing RGC death, as detected by 
fluorogold labeling. HO-1 has been reported to act as an 
antioxidant [27]. The protective properties of CJDHW 
towards ischemia-injured retinal cells such as amacrine 
cells and RGCs may be attributable, at least in part, to 
the antioxidative effects resulting from the overexpres-
sion of HO-1 (Fig. 7; Table 7).
P-p38 and MMP-9 are both upregulated during brain 
ischemia. Under certain circumstances in astrocytes, 
MMP-9 is activated via the p38 MAPK pathway. The 
results of the current study showed a significant increase 
in the expression of MMP-9 mRNA in the retina follow-
ing 60 min of ischemia plus 24 h of reperfusion (Fig. 7; 
Table  7), which was consistent with the results of a 
recent report [23]. This upregulation also coincided 
a1 b1 c1 d1




















































































































































Fig. 7 Western blotting. The antibodies against Bcl‑2 (a1), HO‑1 (a1), P‑p38 (c1), MMP‑9 (d1) and β‑actin are respectively shown as 26, 34.6, 43, 
92~96 and 43‑kDa bands. Each bar represents the ratio of Bcl‑2 (n = 4–9; a2), HO‑1 (n = 4; b2), P‑p38 (n = 4‑9; c2), or MMP‑9 (n = 4–5; d2) to 
β‑actin. * or †represents significance (P < 0.05; Group 1 vs. 2) or significance (P < 0.05; Group 2 vs. 4, I/R + CJDHW4.2; Group 2 vs. 5, SB203580), 
respectively. Additionally, for P‑p38, ** or ††/†represents significance (P < 0.01; Group 1 vs. 2) or significance (P < 0.01/P < 0.05; Group 2 vs. 5/Group 2 
vs. 4), respectively. These 5 Groups included Group 1 as well as Groups 2, 3, 4 and 5 [(the retina subjected to ischemia plus reperfusion respectively 
pretreated with vehicle (I/R + Vehicle), 2.8 g/kg/day of CJDHW (I/R + CJDHW2.8), 4.2 g/kg/day of CJDHW (I/R + CJDHW4.2) and SB203580 (p38 
MAPK inhibitor)]. The results are presented as the mean ± SD
Table 7 Western blotting. The ratios of  the protein expression levels of  Bcl-2, HO-1, P-p38 or MMP-9 relative to  that 
of β-actin
This study included 5 Groups, namely, Group 1 (the sham procedure retina) as well as Groups 2, 3, 4 and 5 [(the retina subjected to ischemia plus reperfusion 
respectively pretreated with vehicle (I/R + vehicle), 2.8 g/kg/day of CJDHW (I/R + CJDHW2.8), 4.2 g/kg/day of CJDHW (I/R + CJDHW4.2) and SB203580 (p38 MAPK 
inhibitor)]. * or † represents significance (P < 0.05; Group 1 vs. 2) or significance (P < 0.05; Group 2 vs. 4; Group 2 vs. 5), respectively. Additionally, for P-p38, ** or †† 
represents significance (P < 0.01; Group 1 vs. 2) or significance (P < 0.01; Group 2 vs. 5; Group 2 vs. 4), respectively. The results are mean ± SD (Bcl-2, n = 4–9; HO-1, 
n = 4; P-p38, n = 4–9; MMP-9, n = 4–5). CJDHW Chi-Ju-Di-Huang-Wan
Group 1 2 3 4 5
Bcl‑2/β‑actin (n = 4‑9) 1.06 ± 0.25 0.78 ± 0.08* 0.83 ± 0.11 1.80 ± 0.34† Not available
HO‑1/β‑actin (n = 4) 0.27 ± 0.12 0.99 ± 0.20* 1.46 ± 0.99 4.15 ± 2.08† Not available
P‑p38/β‑actin (n = 4‑9) 0.15 ± 0.06 1.12 ± 0.18** 0.83 ± 0.21 0.57 ± 0.18†† 0.18 ± 0.07††
MMP‑9/β‑actin (n = 4‑5) 0.25 ± 0.26 0.70 ± 0.23* 0.44 ± 0.15 0.39 ± 0.10† 0.21 ± 0. 07††
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with a significantly increase in the level of P-p38. Nota-
bly, however, these increases in the levels of MMP-9 and 
P-p38 were significantly attenuated after pretreating the 
rats with either CJDHW or the p38 MAPK inhibitor, 
SB203580. CJDHW could downregulate MMP-9 expres-
sion by inhibiting the p38 MAPK pathway.
Ischemia might be involved in diabetic retinopathy 
(DR) [6], neovascular age-related macular degeneration 
[7] and central/branch retinal vascular occlusion [4]; and 
anti-VEGF antibodies and various steroids are currently 
used in clinical practice to treat these conditions [28]. 
However, these approaches are not completely effec-
tive for treating vision-threatening ocular disorders [29]. 
For example, poor visual outcomes have been reported 
in some patients treated with anti-VEGF and steroidal 
agents, even though ocular hemorrhage and macular 
edema were successfully controlled in these patients. 
There is therefore an urgent need to develop agents that 
use novel mechanisms of action against ischemic ocular 
disorders, such as inhibitors of p38 MAPK and MMP-9. 
The increased levels of P-p38 and subsequent overexpres-
sion of MMP-9 detected during the current study were 
linked to retinal ischemia and/or wet age-related macular 
degeneration (wAMD). In such circumstances, based on 
the current results, CJDHW might provide an alternative 
way to deal with these defined vision-threatening retinal 
ischemic disorders.
Hayreh et  al. [30, 31] used 38 elderly, atherosclerotic 
and hypertensive rhesus monkeys (similar to the char-
acteristics of most patients with CRAO) to show that 
CRAO lasting for approximately 240 min results in mas-


































Fig. 8 Gel zymography. An example of a gelatin zymogram (a) used for the quantification of matrix metalloproteinase‑9 (MMP‑9) quantitation 
protein expression by densitometry. Gelatinolytic bands of 72 and 97 kDa corresponded to MMP‑2 and active MMP‑9, respectively. Lane 1, the 
sham procedure retina (Group 1); Lane 2, the vehicle‑pretreated ischemic retina (I/R + Vehicle; Group 2); Lane 3, the SB203580 (p38 MAPK inhibitor)‑
pretreated ischemic retina (I/R + SB203580; Group 5); Lanes 4 and 5, the ischemic retina respectively pretreated with 4.2 g/kg/day (I/R + CJDHW4.2; 
Group 4) and 2.8 g/kg/day of CJDHW (I/R + CJDHW2.8; Group 3). Each bar (b) indicates the mean ± SD (B; n = 4–5). **indicates significance 
(P < 0.01; Group 1 vs. 2). ††indicates significance (P < 0.01; Group 2 vs. 4; Group 2 vs. 5). †indicates significance (P < 0.05; Group 2 vs. 3). In contrast 
to the results for MMP‑9, the expression of MMP‑2, when measured at 24 h after ischemia and pretreatment with vehicle (Group 2) or CJDHW4.2 
(Group 4)/CJDHW2.8 (Group 3), was found to have a similar protein expression level to that of the control Group (Sham; Group 1)
Table 8 Gel zymography
The ratios of the protein expression levels of MMP-9 relative to that of β-actin
This study included 5 Groups, namely, Group 1 (the sham procedure retina) as well as Groups 2, 3, 4 and 5 [(the retina subjected to ischemia plus reperfusion 
respectively pretreated with vehicle (I/R + vehicle), 2.8 g/kg/day of CJDHW (I/R + CJDHW2.8), 4.2 g/kg/day of CJDHW (I/R + CJDHW4.2) and SB203580 (p38 MAPK 
inhibitor)]
CJDHW Chi-Ju-Di-Huang-Wan
** indicates significance (P < 0.01; Group 1 vs. 2)
††  indicates significance (P < 0.01; Group 2 vs. 4; Group 2 vs. 5). †indicates significance (P < 0.05; Group 2 vs. 3). The results are mean ± SD (n = 4–5)
Group (n = 4–5) 1 2 3 4 5
MMP‑9/β‑actin 1.00 ± 0.00 5.03 ± 1.57** 3.05 ± 0.88† 1.35 ± 0.41†† 1.49 ± 0.47††
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Moreover, in human BRAO studies, 46 % (24 of 52) of the 
eyes tested in the series reported by Mason et al. [32] and 
100 % (5 of 5) of eyes tested in the series reported by Hsu 
et al. [33] were found to present with best corrected vis-
ual acuity (BCVA) values of <20/40. Furthermore, Mason 
et al. [32] indicated that 75 % (18 of 24) of the untreated 
eyes with a poor presentation of BCVA (<20/40) had 
a final BCVA of <20/40. Moreover, only 14  % (2 of 14) 
of eyes with a BCVA of ≤20/100 were improved to a 
BCVA of ≥20/40. There was a high rate of spontaneous 
improvement in the vision of BRAO eyes that had an ini-
tial poor BCVA, although these data should be treated 
with caution because these events are generally associ-
ated with irreversible retinal damage. The Eurocondor 
project [34] assessed whether topical brimonidine and 
somatostatin could be used to prevent or arrest neurode-
generation, and the development and progression of the 
“early” stages of DR. Pretreatment with CJDHW could 
become clinically important as a preventive approach for 
patients with a family history of AMD or diabetes, and/
or when there are predisposing factors related to CRAO 
or BRAO, hypertension, coronary/carotid artery disease, 
hyperlipidemia or heart valve disorder.
Conclusions
CJDHW inhibited apoptosis, increased antioxida-
tive activity, downregulated MMP-9 and inhibited p38 
MAPK.
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